VRCA Description — Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. Co.'s product pipeline consists of: VP-102, which is a propriety drug-device combination that contains a good manufacturing practices-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, external genital warts and common warts; VP-315, which is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma; and VP-103, which is a cantharidin based drug device combination for the potential treatment of plantar warts.
|
|
Free VRCA Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.67 out of 4) 64th percentile
(ranked higher than approx. 64% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |